louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06696651: Electrical Muscle Stimulation Effect Versus Myofascial Release on Quality of Life in Female Fibromyalgia
Official title: Electrical Muscle Stimulation Effect Compared With Myofascial Release on Quality of Life in Female Fibromyalgia
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Electric Stimulation
Myofascial Release
Fibromyalgia
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-11-20
Enrollment: 60
Sex: FEMALE
Minimum age (years): 45
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: the study was done to investigate the effect of Electrical Muscle Stimulation as muscle strengthening versus the effect of myofascial releasing on quality of life in female fibromyalgia patients while following Mediterranean diet.

Detailed description: Fibromyalgia is a chronic pain condition characterized by unrefreshing sleep, physical exhaustion, and cognitive difficulties. It affects all populations worldwide and requires a diagnosis of widespread pain for at least three months. People with Fibromyalgia show abnormal endogenous pain modulation, including reduced conditioned pain modulation and exercise-induced hypoalgesia. Exercise is considered a first-line treatment for Fibromyalgia. Electrical myostimulation has been shown to improve pain, sleep subscales, and quality of life. A potential causal link between Fibromyalgia and micronutrient deficiency has been suggested. The study focuses on fibromyalgia, which affects mostly females and is difficult to diagnose easily. Electrical myostimulation and myofascial release are effective treatments for Fibromyalgia.

Eligibility criteria: Inclusion Criteria:

1. Sixty females have diagnosed suffering from fibromyalgia syndrome.
2. Their ages will be ranged from 45 to 55 years old.
3. Their body mass index will be ranged from 25 to 34 ( overweight and obese type 1)
4. They have willingness to participate in this study.

Exclusion Criteria:

1. Peripheral vascular diseases.
2. Drug abuse.
3. Smokers.
4. Chest disease. ( either obstructive or restrictive ).
5. Clinical signs of sever cardiac events ( eg. Congestive heart disease).

Primary outcomes:
measure: Assessment of change of body mass index
timeFrame: at baseline and after 6 weeks
measure: Assessment of change of pressure pain threshold using algometry
timeFrame: at baseline and after 6 weeks
Secondary outcomes:
measure: assessment of fibromyalgia using Fibromyalgia Impact Questionnaire
timeFrame: at baseline and after 6 weeks
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: out-patient clinic, new Cairo hospital
Study officials:
References:
Clinical trial NCT00651651: Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 80/4.5
Official title: A 12 Week Randomized, Double-blind, Double-Dummy, Placebo-controlled Trial of Symbicort TM (160/4.5mcg) Versus Its Mono-Products (Budesonide and Formoterol) in Children (at Least 6years of Age) and Adults With Asthma-SPRUCE 80/4.5
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Asthma
Keywords: Asthma
Symbicort
budesonide/formoterol
budesonide
formoterol
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2008-04-03
Enrollment: 450
Sex: ALL
Minimum age (years): 6
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare Symbicort with its monocomponents budesonide and formoterol in the treatment of asthma in children and adults


Eligibility criteria: Inclusion Criteria:

* At least 6 years of age
* Diagnosis of asthma
* Baseline lung function test results as determined by protocol and required and received treatment with inhaled corticosteroids and/or lung treatments specified in protocol within the timeframe and doses specified in the protocol

Exclusion Criteria:

* Severe asthma
* Has required treatment with any non-inhaled corticosteroids within previous 4 weeks, has sensitivity to drugs specified in the protocol or requires treatment with beta-blockers
* Had cancer within previous 5 years or currently has any other significant disease or disorder as judged by the investigator

Primary outcomes:
measure: 12 hour serial FEV1 measurements and withdrawals due to asthma exacerbation
timeFrame: FEV1: before start of tretment and at 2 and 12 weeks after start of treatment. Withdrawals: throughout the treatment period
Secondary outcomes:
measure: Lung function, asthma symptoms, use of rescue medication, adverse events and other safety assessments
timeFrame: Throughout the treatment period
Other outcomes:
Locations:
Study officials:
affiliation: AstraZeneca
name: Catherine Bonuccelli
role: STUDY_DIRECTOR
References:
citation: Murphy KR, Uryniak T, Martin UJ, Zangrilli J. The effect of budesonide/formoterol pressurized metered-dose inhaler on predefined criteria for worsening asthma in four different patient populations with asthma. Drugs R D. 2012 Mar 1;12(1):9-14. doi: 10.2165/11630600-000000000-00000.
Clinical trial NCT01524354: Depth of Anesthesia in Cardiac Surgery
Official title: Monitoring of Anesthetic Depth During Surgical Correction of Acquired Valvular Disorders
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Heart Valve Diseases
Keywords: depth of anesthesia
valve surgery
Lead sponsor: Northern State Medical University
Sponsor class: OTHER
First posted: 2012-02-01
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of our study was to evaluate the significance of monitoring anesthetic depth for the conduct of anesthesia and the early postoperative period in patients subjected to surgical correction of combined valvular disorders.

Detailed description: Our aim was to evaluate the effect of monitoring anesthetic depth on duration of postoperative mechanical ventilation and ICU stay after surgical correction of combined valvular disorders.

Eligibility criteria: Inclusion Criteria:

* requirement of surgical correction of two or more valves

Exclusion Criteria:

* no

Primary outcomes:
measure: duration of postoperative mechanical ventilation
timeFrame: 24 hours postoperatively
Secondary outcomes:
measure: length of ICU stay
timeFrame: 7 days postoperatively
Other outcomes:
Locations:
Study officials:
affiliation: Northern State Medical Univercity
name: Mikhail Y Kirov, MD, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00735254: Pulsed Dye Laser and Affirm Laser in the Treatment of Abdominoplasty Scars
Official title: Pulsed Dye Laser and Affirm Laser in the Treatment of Abdominoplasty Scars
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Abdominoplasty Scars
Keywords: post
surgical
Lead sponsor: The Cleveland Clinic
Sponsor class: OTHER
First posted: 2008-08-14
Enrollment: 3
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to examine the effect of using a pulsed dye laser (the VBEAM), a non-ablative laser (the Affirm) and a combination of both lasers to improve the appearance of your surgical scar. Both the pulsed dye laser and Affirm laser are approved by the US Food and Drug Administration (FDA) for the treatment of scars. Surgical scars are a type of scar that can benefit from laser therapy. Redness and the appearance of small blood vessels near the surface of the skin (telangiectasias) develop in such scars as part of the normal healing process and usually spontaneously remit, but often slowly and incompletely. In many cases, lasers can accelerate the clearing of this redness and also improve scar texture.

Detailed description: In summary, we will perform a total of three laser treatments. A personal interview, clinical examination, and a photograph will be taken at each visit. At the end of the three treatments, a final personal interview, clinical evaluation and photograph will be taken to document the effects of the laser treatments. At the end of the study, the patient will have the option to receive two additional laser treatments four weeks apart, also at no cost, to the entire scar.

Eligibility criteria: Inclusion Criteria:

* Age 18 years and older
* No significant medical illness
* Surgical procedure that involves closure of the transverse abdominal incision performed in the department of dermatology and plastic surgery at the Cleveland Clinic main campus.
* Subjects with the willingness and ability to understand and provide informed consent

Exclusion Criteria:

* Under 18 years of age
* Pregnancy or Lactation
* Subjects currently taking blood thinners or who have had chemotherapy or radiation within the last 6 months
* Subjects with liver/kidney disease, diabetes mellitus, hypertension, connective tissue disease or who are immunocompromised
* Subjects with a known susceptibility to keloid formation or hypertrophic scarring
* Subjects who are unable to understand the protocol or to give informed consent
* Subjects with mental illness
* Subjects with obvious non-healing wound

Primary outcomes:
measure: Efficacy of PDL vs Affirm Laser vs Combined Laser Treatments in Appearance of Surgical Scar
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Cleveland
country: United States
facility: Cleveland Clinical Foundation
state: Ohio
Study officials:
affiliation: The Cleveland Clinic
name: Rebecca Tung, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01812954: Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Psoriasis
Keywords: moderate-to-severe psoriasis
cost utility analysis
cost effectiveness analysis
systemic treatment
Lead sponsor: Technische Universität Dresden
Sponsor class: OTHER
Collaborators: name: Merck Sharp & Dohme LLC
First posted: 2013-03-18
Enrollment: 1
Sex: ALL
Minimum age (years): 16
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients with moderate-to-severe psoriasis, who require systemic treatment to adequately control the disease

Brief summary: This study is health economic analysis of medicinal treatment options for moderate-to-severe psoriasis vulgaris from the societal perspective. Efficacy data and other clinical outcomes will be derived from an up-to-date meta-analysis of randomized clinical trials (RCTs) for moderate-to-severe psoriasis. Direct and indirect costs will be extracted from various different sources, including summary of product characteristics (SPCs) and the German S3 guideline on psoriasis care, health care utilization data and official statistics.

The study aims to investigate the comparative cost-effectiveness of biologic and conventional systemic treatments currently (as of June 1st, 2012) approved for moderate-to-severe plaque-type psoriasis in Germany. Effectiveness will be measured by means of the pooled (Psoriasis Area and Severity Index) PASI-75 response rates as reported in RCTs Direct cost as well as indirect cost will be considered.


Eligibility criteria: Inclusion Criteria:

-diagnosis of moderate-to-severe psoriasis

Exclusion Criteria:

-

Primary outcomes:
measure: Cost per quality-adjusted life year (QALY) gained through treatment with each individual agent compared to supportive care as well as compared to placebo
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University Dresden
name: Jochen Schmitt, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03428854: Adenomyosis: Genomic Mechanisms and Biological Response
Official title: Adenomyosis: Genomic Mechanisms and Biological Response
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Adenomyosis
Abnormal Uterine Bleeding
Lead sponsor: University of Texas Southwestern Medical Center
Sponsor class: OTHER
First posted: 2018-02-12
Enrollment: 0
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Women with abnormal uterine bleeding due to adenomyosis

Brief summary: Examination of genomic and biologic responses to LNG-IUS in patients with adenomyosis.

Detailed description: Examination of genomic and biologic responses to LNG-IUS in patients with adenomyosis.

Eligibility criteria: Inclusion Criteria:

* Abnormal bleeding in the presence of Adenomyosis as demonstrated by MRI

Exclusion Criteria:

* Other causes of abnormal bleeding such as fibroids, endometrial polyps, malignancy
* Presence of endometriosis

Primary outcomes:
measure: Menstrual blood loss
timeFrame: 12 months
Secondary outcomes:
measure: Quality of Life
timeFrame: 12 months
measure: Pain
timeFrame: 12 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01199354: Skin Sparing Mastectomy and Immediate Breast Reconstruction With Latissimus Dorsi Flap After Neoadjuvant Chemotherapy and Radiotherapy (M-RIC)
Official title: Phase II Study: Assessing the Feasibility and Morbidity of Skin Sparing Mastectomy and Immediate Breast Reconstruction With Latissimus Dorsi Flap After Neoadjuvant Chemotherapy and Radiotherapy in Invasive Breast Carcinoma.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Breast Carcinoma
Keywords: Invasive breast carcinoma
Lead sponsor: Clinique Clementville
Sponsor class: OTHER
First posted: 2010-09-10
Enrollment: 80
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: The aim of the study is to evaluate the feasibility and morbidity of skin sparing mastectomy and immediate breast reconstruction with latissimus dorsi flap after neoadjuvant chemotherapy and radiotherapy in invasive breast carcinoma.


Eligibility criteria: Inclusion Criteria:

* Women \< 75 year old
* Invasive breast carcinoma, indication for mastectomy
* Women Health Organization (WHO) score of 0 and 1, primary chemotherapy, external radiotherapy performed less than 8 week earlier...

Exclusion Criteria:

* Women older than 75
* Metastatic breast carcinoma
* Antecedents of previously treated homolateral breast carcinoma
* Documented cancer progression
* Smoker at the moment of the indication surgery
* Known diabetes, neoadjuvant hormonal treatment...

Primary outcomes:
measure: Incidence of skin necrosis
Secondary outcomes:
measure: Rate of histological remission of the surgical specimen based on the anatomopathological examination
Other outcomes:
Locations:
city: Avignon
country: France
facility: Polyclinique Urbain V
city: Avignon
country: France
facility: Polyclinique Urbain V
city: Clermont-Ferrand
country: France
facility: Centre Jean Perrin
city: Grenoble
country: France
facility: Groupe Hospitalier Mutualiste Clinique les Eaux Claires
city: Lyon
country: France
facility: Centre Léon Bérard
city: Marseille
country: France
facility: Institut Paoli Calmettes
city: Marseille
country: France
facility: Institut Paoli Calmettes
city: Montpellier
country: France
facility: Clinique Clementville
city: Montpellier
country: France
facility: CRLCC Val d'Aurelle
city: Saint Martin d'Hères
country: France
facility: Clinique Belledonne
city: Toulouse
country: France
facility: Institut Claudius Regaud
Study officials:
affiliation: Clinique Clementville
name: Cécile Zinzindhoue
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04236154: "Prescribing" Exercise to Cancer Patients At High-Risk for Falls
Official title: "Prescribing" Exercise to Cancer Patients At High-Risk for Falls
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Cancer
Keywords: Exercise, Falls
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
Collaborators: name: Andersen Foundation
First posted: 2020-01-22
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: The investigator will incrementally increase the exercise prescription for groups of patients.
Primary purpose: SUPPORTIVE_CARE

Brief summary: Falls are common and catastrophic in cancer patients. Cancer patients are vulnerable to falls due to muscle loss. In prescribing exercise in a data driven manner to cancer patients, our hypothesis is this "prescription" for exercise will eventually be demonstrated to reduce the occurrence of injurious falls.


Eligibility criteria: Inclusion Criteria:

* Any cancer diagnosis, as documented in medical record, other than non-melanoma skin cancer.
* No issues such as unstable angina or loss of a limb that would preclude exercise.

Exclusion Criteria:

* Diagnosis of non-melanoma skin cancer
* Unstable angina
* Loss of limb, which limits exercise capabilities at the discretion of the Principal Investigators
* Pregnant women

Primary outcomes:
measure: ABC Activities Specific Balance Confidence Scale (exploratory outcome)
timeFrame: Change from baseline ABC scale at 4-6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Aminah Jatoi, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00516854: A Study of the Use of Combination of Anti-cholinergic and Minor Tranquilliser in the Treatment of Non-cardiac Chest Pain - a Double Blind Placebo Controlled Study
Official title: A Study of the Use of Combination of Anti-cholinergic and Minor Tranquilliser in the Treatment of Non-cardiac Chest Pain - a Double Blind Placebo Controlled Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Chest Pain
Keywords: Non-cardiac chest pain
Lead sponsor: Hospital Authority, Hong Kong
Sponsor class: OTHER_GOV
Collaborators: name: The University of Hong Kong
First posted: 2007-08-16
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Non-cardiac chest pain is a common clinical problem encountered in our practice but at present, the results of treatments are unsatisfactory. The pathogenesis remains unknown but altered motility of the esophagus and psychological factors including anxiety have been implicated as important factors. Reports of the single use of anticholinergic drugs and anxiolytics have yielded conflicting results, has been demonstrated to yield marginal or of no value. However the use of the combination therapy, especially with a double blind fashion have not been reported. On that basis, we propose to use a combination of anti-cholinergic and tranquilliser for the symptomatic treatment of non-cardiac chest pain. The aim of this study is to evaluate the efficacy of combination therapy of anti-cholinergic and anxiolytic drugs in the treatment of non-cardiac chest pain.


Eligibility criteria: Inclusion Criteria:

* Ambulatory patients over the age of 18
* Patients who are normal endoscopically
* Patients who do not have symptomatic reflux disease
* Patient who have normal coronary angiogram or patient with normal exercise radionuclide scan or patient with normal persantin radionuclide scan.

Exclusion Criteria:

* Patients with history of significant cardiac, renal, pulmonary or hepatic diseases,
* Patients with history of dyspepsia or peptic ulcer diseases
* Patient with documented reflux diseases.
* Patient on drugs that affect gastrointestinal motility in the past 2 weeks
* Patients who are pregnant or lactating
* Patients who are suffering from costochrondritis
* Patients who are known to be sensitive to benzodiazepine or anti-cholinergic
* Patients with glaucoma and benign prostatic hypertrophy

Primary outcomes:
measure: Symptoms scores, quality of life
timeFrame: 12 Weeks
Secondary outcomes:
measure: Compliance
timeFrame: 12 Weeks
measure: Adverse effects
timeFrame: 12 Weeks
Other outcomes:
Locations:
city: Hong Kong
country: China
facility: Queen Mary Hospital
Study officials:
affiliation: Department of Medicine, Queen Mary Hospital/ The University of Hong Kong
name: Ting Kin Cheung, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06576154: The Role of Antibiotic Prophylaxis in Lowering Wound Infection Rates Post-Open Repair of Primary Elective Groin Hernias in High-Risk Patients
Official title: The Role of Antibiotic Prophylaxis in Lowering Wound Infection Rates Post-Open Repair of Primary Elective Groin Hernias in High-Risk Patients: A Randomized Control Trial.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: Antibiotic Prophylaxis
Wound Infection
Groin Hernia
Keywords: Groin hernia
Postoperative complications
Wound infection
Surgical site infection
High-risk patients
Lead sponsor: University of Aleppo
Sponsor class: OTHER
Collaborators: name: Aleppo University Hospital Resident Team
First posted: 2024-08-28
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study aims to investigate the impact of antibiotic prophylaxis on reducing wound infection rates following open repair of primary elective groin hernias in high-risk patients.

Detailed description: This study will be a randomized controlled trial involving high-risk patients undergoing open repair of primary elective groin hernias. Participants will be randomized into two groups: one receiving antibiotic prophylaxis and the other serving as the control group. The study will assess the incidence of wound infections postoperatively in both groups to determine the effectiveness of antibiotic prophylaxis in lowering infection rates.

Eligibility criteria: Inclusion Criteria:

* Volunteer to participate in the study.
* Elderly patients aged over 60 years.
* Patients with Diabetes.
* Or obese patients with a BMI greater than 35.
* Or immunocompromised patients.
* Or American Society of Anesthesiologists (ASA) physical status classification 2 or more, with a history of more than 10 years.

Exclusion Criteria:

* Non-cooperative patients for regular follow-up.
* Therapeutic Indication for.

Primary outcomes:
measure: Overall Complication Rate
timeFrame: up to 30 days after the surgery.
measure: Wound infection/ Surgical site infection
timeFrame: up to 30 days after the surgery.
Secondary outcomes:
measure: Mortality Rate
timeFrame: up to 30 days after the surgery.
measure: Hospital stay
timeFrame: up to 30 days after the surgery.
Other outcomes:
measure: Other Adverse events
timeFrame: up to 30 days after the surgery.
Locations:
city: Aleppo
country: Syrian Arab Republic
facility: Aleppo University Hospital
Study officials:
References: